Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents
Abstract Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demon...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2018
|
| Subjects: | |
| Online Access: | https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|